Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tissue Regenix Group (LSE:TRX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tissue Regenix Group's Enterprise Value for the quarter that ended in Dec. 2025 was £13.24 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £-7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group EV-to-EBIT Related Terms
Tissue Regenix Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:TRX vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Tissue Regenix Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's EV-to-EBIT falls into.
Tissue Regenix Group's current Enterprise Value is £11.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tissue Regenix Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £-7.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (LSE:TRX) has a EV-to-EBIT of -1.57 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's EV-to-EBIT too high?
Tissue Regenix Group's current EV-to-EBIT is -1.57.
How does Tissue Regenix Group's EV-to-EBIT compare to VRTX and REGN?
Tissue Regenix Group's EV-to-EBIT of -1.57 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.55, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current EV-to-EBIT is -1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current EV-to-EBIT of -1.57. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current EV-to-EBIT is -1.57. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current EV-to-EBIT is -1.57 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:TRX has been successfully added to your 
